Targeted Renal Therapy (TRT) is the delivery of physician-specified therapeutic agents directly to the kidneys via the renal arteries for patients at risk or with demonstrated symptoms of acute kidney injury. The Benephit infusion system is a proprietary, low-profile, selective infusion catheter system that delivers therapeutic agents directly to the renal arteries through a dedicated infusion catheter. Benephit is ideal for use during peripheral and coronary diagnostic and interventional procedures, as well as cardiovascular surgery. It has been shown to be easy to use, safe and broadly applicable to a wide cross section of patients, and addresses a wide range of insults in a variety of procedural settings that can lead to acute kidney injury.